The standard cagrilintide monotherapy titration follows this schedule: 0.25 mg weekly for weeks 1-4, then 0.5 mg for weeks 5-8, then 1.0 mg for weeks 9-12, then 1.7 mg for weeks 13-16, and finally 2.4 mg for week 17 onward as the maintenance dose
Many patients find that supportive strategies like proper hydration, gut health support, and working closely with their provider can help manage these effects effectively
This is one of the more serious side effects and might change the way your doctor chooses to treat the problem
Patients with pre-existing kidney disease should discuss creatine use with their provider, and baseline kidney function testing with periodic monitoring is recommended
I also work as a Customer Advocate for BCBS, so I understand both the patient side and the insurance side
Instead of working with two separate peptide vials, researchers can use one combined blend for studies that require both peptide components in the same protocol